OMER, Israel, April 16, 2015 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced that results of an ex-vivo study are being revealed today at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Meeting, currently taking place through April 17th at the Gaylord Opryland Hotel and Convention Center in Nashville, Tennessee. The poster presentation, entitled Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE): results from an ex vivo simulation trial to assess the efficacy of the procedure by comparing stapling position and gastric yield pressures, will be presented by Tae-Geun Gweon, MD, of Boston Children's Hospital, Harvard Medical School.
The aim of this trial was to identify the ideal stapling location in relation to the gastroesophageal junction (GEJ) in a validated simulation model. It evaluated the MUSE system in eight ex-vivo porcine stomachs, with stapling distances varying from 5mm to 45mm from the GEJ. Investigators observed that procedures with a stapling distance of at least 30mm superior to the GEJ resulted in an improved lower esophageal sphincter valve mechanism measured as an increase in gastric yield pressure (GYP) in comparison to baseline. The study concluded that there should be a minimal distance of 30mm between each stapling location and the GEJ to create an efficient valve using the MUSE system.
"These trial results offer valuable insight for optimizing results and enhancing long-term patient outcomes using the MUSE system," said Chris Rowland, CEO of Medigus. "The SAGES Annual Meeting represents an important opportunity to connect with esteemed clinicians in the GI community and to provide critical updates on novel therapeutic options, such as MUSE."
MUSE offers a new treatment option for the millions of Americans who suffer from persistent gastroesophageal reflux disease, or GERD, and are unable to obtain long-term relief from available drug therapies or unwilling to undergo invasive surgical procedures. This intuitive device merges the latest breakthroughs in visualization, ultrasound and surgical stapling capabilities into a single platform, which allows a single physician or surgeon to administer the anterior partial fundoplication.
For more information about MUSE, please visit the Medigus booth in the Ryman Exhibit Hall C, Booth # 644.
The MUSE system is FDA cleared and CE marked.
The mission of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) is to improve quality patient care through education, research, innovation and leadership, principally in gastrointestinal and endoscopic surgery. The SAGES 2015 Annual Meeting will be held at the Gaylord Opryland Hotel and Convention Center in Nashville, TN, April 15 though 17. For more information about the annual meeting visit www.sages2015.org or www.sages.org.
The MUSE system is a leading technology in Natural Orifice Endoscopic Surgery procedures. The single operator system performs anterior partial fundoplication with standard surgical staples in a less invasive way, compared to other surgical procedures. Its intuitive endosurgical platform consists of a single use flexible surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder. The endostapler, which resembles an endoscope, is designed to be operated by a single user, includes a handle with controls, an 80cm flexible shaft, a 5cm rigid section holding a cartridge with 5 standard 4.8mm titanium surgical staples, a ratchet controlled one-way articulating section, and a distal tip. The MUSE system is FDA cleared and CE marked. Medigus anticipates that the new Category 1 Current Procedural Terminology (CPT®) code, recently created by The American Medical Association (AMA) for Esophagogastric Fundoplasty Trans-Orifice Approach procedures, would be the code used for MUSE.
Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. Medigus is a pioneer developer of a unique proprietary endoscopic device, the MUSE™ system, to treat gastroesophageal reflux disease (GERD), one of the most common chronic diseases in the western world. As an expert in micro-endoscopic devices, Medigus has developed a range of micro CMOS (complementary metal-oxide semiconductor) and CCD (charge-coupled device) video cameras, including micro ScoutCam™ 1.2, which to the best of the company's knowledge, is the smallest in the world. These innovative cameras are suitable for both medical and industrial applications. The MUSE system incorporates Medigus' revolutionary micro ScoutCam technology. Based on its proprietary technologies, Medigus designs and manufactures endoscopy and micro camera systems for partner companies, including major players in the medical and industrial fields. The company is committed to providing integrated solutions to meet all of its customer's imaging needs. Medigus is traded on the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.microscoutcam.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. By their nature, Forward-Looking Statements involve uncertainties which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Among the factors which may cause the actual results to differ from the Forward-Looking Statements are changes in the target market and the introduction of competitive products, regulatory, legislative and policy changes, and clinical results. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.
CONTACT: MEDIA CONTACT: Chantal Beaudry/ Carrie Yamond Lazar Partners Ltd. 212-867-1762 firstname.lastname@example.org email@example.com INVESTOR RELATIONS: Miri Segal-Scharia Hayden/ MS-IR LLC 917-607-8654 firstname.lastname@example.org